Structural investigations of coronavirus spike protein

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1R21AI183188-01A1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2024
    2026
  • Known Financial Commitments (USD)

    $247,750
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    ASSISTANT PROFESSOR Syed Saif Hasan
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF MARYLAND BALTIMORE
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

PROJECT SUMMARY The spike (S) protein decorates the surface of coronavirus (CoV) particles such as SARS-CoV-2 and enables CoV's to enter and infect host cells. The S protein is the immunogen in genetic and subunit vaccines against COVID-19, which were critical in controlling the COVID-19 global pandemic. In cells that are infected with CoV's or have received a genetic vaccine, the S protein is synthesized in the mammalian cell endoplasmic reticulum (ER), and then trafficking via the secretory pathway consisting of ER, Golgi network, and plasma membrane (PM). This secretory trafficking of S is bidirectional between ER and Golgi, which are the secretory organelles that provide the enzymatic machinery for post-translational modifications, remodeling, and maturation. This includes enzymes for N-glycosylation, which modulates S folding, viral entry, and interactions with the host immune system. Structure-function investigations have shown that N-glycans modulate conformations of S domains, such as the immunogenic receptor binding domain (RBD). Therefore, S N-glycans play a direct role in immune response modulation. As such, N-glycan maturation changes in S due to tissue-, population-, ethnicity- , and age-specific differences in biosynthetic machinery have the potential to dramatically alter infection CoV outcomes and genetic vaccine immunogenicity. Yet little is known about the atomic-level consequences of N- glycan maturation on S structure-function. This is mainly due to the inability to arrest S in various stages of trafficking and N-glycan maturation. In this grant application, we will use an innovative new methodology to control S trafficking. Purified samples of these novel S constructs will be structurally characterized using latest cryoEM and computational tools and assayed for interactions with highly potent conformation-sensitive antibodies. This will generate unprecedented and the first insights into structural modulation of S conformations and epitopes by N-glycan maturation. Collectively, these investigations will be highly significant in providing fundamental insights into secretory trafficking and the role of bidirectional trafficking of S in modulating N-glycan maturation and RBD conformations. These data will open avenues for the design of a new generation of S-based vaccines with improved immunogenicity. In the future, the insights from this research will serve as a platform to inform the design of vaccines against enveloped viruses that pose global health challenges such as HIV and influenza, which utilize the host cell ER-Golgi-PM secretory pathway to acquire immunity evading glycans.